指南与共识乳腺癌

ASCO 2018版:HER2阳性晚期乳腺癌的系统治疗指南更新

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.
指南 / 共识 · J Clin Oncol · 2018-06-25

ASCO专家小组针对2018年HER2阳性晚期乳腺癌系统治疗及CNS转移进行定向系统综述,共纳入622篇文献,未发现需修改2014版推荐的额外证据。指南推荐一线曲妥珠单抗+帕妥珠单抗+紫杉类,二线T-DM1,三线可选其他HER2靶向联合或T-DM1(若未用过)。

要点

  • 一线推荐曲妥珠单抗+帕妥珠单抗+紫杉类,二线推荐T-DM1
  • 三线可提供其他HER2靶向联合或T-DM1(若未用过),或帕妥珠单抗(若未用过)
  • HER2靶向治疗持续至进展或不可接受毒性;化疗最佳疗程至少4-6个月或至最大缓解

核心结论

  • 针对2018年HER2阳性晚期乳腺癌的系统治疗,未发现需修改2014版ASCO推荐的额外证据。

研究设计与样本

  • ASCO专家小组对系统治疗和CNS转移进行定向系统文献综述,共识别622篇文章。

主要发现

  • 在622篇文献中,未发现需改变2014版推荐的额外证据。
  • 关注结局包括总生存期、无进展生存期和不良事件。

关键数值与推荐

  • 推荐HER2靶向治疗用于HER2阳性晚期乳腺癌,但临床充血性心力衰竭或左心室射血分数显著降低者需个体化评估。
  • 一线推荐曲妥珠单抗、帕妥珠单抗和紫杉类;二线推荐曲妥珠单抗 emtansine(T-DM1)。
  • 三线推荐其他HER2靶向联合或T-DM1(若未用过),可提供帕妥珠单抗(若未用过)。
  • 化疗最佳疗程至少4-6个月或至最大缓解,取决于毒性和无进展。
  • HER2靶向治疗可持续至进展或不可接受毒性;HR阳性/HER2阳性者可选择标准一线或内分泌联合HER2靶向或内分泌单药(特定患者)。

临床怎么用

  • 对HER2阳性晚期乳腺癌患者,一线选择曲妥珠单抗+帕妥珠单抗+紫杉类,二线选择T-DM1。
  • 三线根据既往治疗选择其他HER2靶向联合或T-DM1(若未用过),或帕妥珠单抗(若未用过)。
  • HER2靶向治疗应持续至进展或不可接受毒性,化疗疗程至少4-6个月或至最大缓解。
  • HR阳性/HER2阳性患者可考虑标准一线或内分泌联合HER2靶向或内分泌单药(特定患者)。
  • 临床充血性心力衰竭或左心室射血分数显著降低者需个体化评估HER2靶向治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To update evidence-based guideline recommendations for practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer to 2018. Methods An Expert Panel conducted a targeted systematic literature review (for both systemic treatment and CNS metastases) and identified 622 articles. Outcomes of interest included overall survival, progression-free survival, and adverse events. Results Of the 622 publications identified and reviewed, no additional evidence was identified that would warrant a change to the 2014 recommendations. Recommendations HER2-targeted therapy is recommended for patients with HER2-positive advanced breast cancer, except for those with clinical congestive heart failure or significantly compromised left ventricular ejection fraction, who should be evaluated on a case-by-case basis. Trastuzumab, pertuzumab, and taxane for first-line treatment and trastuzumab emtansine for second-line treatment are recommended. In the third-line setting, clinicians should offer other HER2-targeted therapy combinations or trastuzumab emtansine (if not previously administered) and may offer pertuzumab if the patient has not previously received it. Optimal duration of chemotherapy is at least 4 to 6 months or until maximum response, depending on toxicity and in the absence of progression. HER2-targeted therapy can continue until time of progression or unacceptable toxicities. For patients with HER2-positive and estrogen receptor-positive/progesterone receptor-positive breast cancer, clinicians may recommend either standard first-line therapy or, for selected patients, endocrine therapy plus HER2-targeted therapy or endocrine therapy alone. Additional information is available at www.asco.org/breast-cancer-guidelines .

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Giordano SH, Temin S, Chandarlapaty S, et al. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018. PMID: 29939838. doi:10.1200/JCO.2018.79.2697

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。